<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Molekulyarnaya Meditsina (Molecular medicine)</journal-id><journal-title-group><journal-title xml:lang="en">Molekulyarnaya Meditsina (Molecular medicine)</journal-title><trans-title-group xml:lang="ru"><trans-title>Молекулярная медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2918</issn><issn publication-format="electronic">2499-9490</issn><publisher><publisher-name xml:lang="en">Russkiy Vrach Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">717227</article-id><article-id pub-id-type="doi">10.29296/24999490-2026-04-02</article-id><article-id pub-id-type="edn">xoxdvc</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original research</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Relationships between growth factors and clinical diagnostic parameters in patients with diabetic foot syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязи факторов роста с клинико-диагностическими параметрами у пациентов с синдромом диабетической стопы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-0168-9925</contrib-id><name-alternatives><name xml:lang="en"><surname>Sycheva</surname><given-names>Darya R.</given-names></name><name xml:lang="ru"><surname>Сычёва</surname><given-names>Дарья Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant Professor, Department of Pathological Anatomy</p></bio><bio xml:lang="ru"><p>ассистент кафедры патологической анатомии</p></bio><email>darya.hardy@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9442-5207</contrib-id><name-alternatives><name xml:lang="en"><surname>Lutsenko</surname><given-names>Yuriy G.</given-names></name><name xml:lang="ru"><surname>Луценко</surname><given-names>Юрий Григорьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Associate Professor of the Department of Faculty Surgery named after Professor K.T. Ovnatanyan; Doctor of Medical Sciences</p></bio><bio xml:lang="ru"><p>доцент кафедры факультетской хирургии им. проф. К.Т. Овнатаняна; Доктор медицинских наук</p></bio><email>hirurgiya.fipo@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7987-4091</contrib-id><name-alternatives><name xml:lang="en"><surname>Kyshenya</surname><given-names>Maria S.</given-names></name><name xml:lang="ru"><surname>Кишеня</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Leading Researcher at the Central Scientific Research Laboratory; Candidate of Medical Sciences</p></bio><bio xml:lang="ru"><p>ведущий научный сотрудник ЦНИЛ; Кандидат медицинских наук</p></bio><email>maria.kishenya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-5544-694X</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramova</surname><given-names>Yulia G.</given-names></name><name xml:lang="ru"><surname>Абрамова</surname><given-names>Юлия Геннадиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Surgeon</p></bio><bio xml:lang="ru"><p>врач-хирург </p></bio><email>liabrams11@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-4770-7254</contrib-id><name-alternatives><name xml:lang="en"><surname>Yasinetskaya</surname><given-names>Elena I.</given-names></name><name xml:lang="ru"><surname>Ясинецкая</surname><given-names>Елена Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5<sup>th</sup> year student of the Faculty of General Medicine No.1 </p></bio><bio xml:lang="ru"><p>студентка V курса лечебного факультета №1 </p></bio><email>elena_yasinetskaya2004@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FSBEI HE Donetsk State Medical University named after M. Gorky</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Донецкий государственный медицинский университет им. М. Горького» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">State Budgetary Institution “Central Clinical Hospital No.9 in Donetsk”</institution></aff><aff><institution xml:lang="ru">ГБУ ДНР «ЦГКБ №9 г. Донецка»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-08-13" publication-format="electronic"><day>13</day><month>08</month><year>2026</year></pub-date><volume>24</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>8</fpage><lpage>14</lpage><history><date date-type="received" iso-8601-date="2026-08-12"><day>12</day><month>08</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-08-12"><day>12</day><month>08</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Russkiy Vrach Publishing House</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ИД "Русский врач"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Russkiy Vrach Publishing House</copyright-holder><copyright-holder xml:lang="ru">ИД "Русский врач"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2031-08-13"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2918/article/view/717227">https://journals.eco-vector.com/1728-2918/article/view/717227</self-uri><abstract xml:lang="en"><p><bold>Aim</bold><bold> </bold>of the study was to establish the relationships between vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB), and transforming growth factor β1 (TGFβ1) and clinical diagnostic parameters in patients with diabetic foot syndrome (DFS) treated with various approaches.</p> <p><bold>Material and methods.</bold> The study included 227 patients with DFS, divided into two groups. The study group included 114 (50.22%) patients who received laser therapy as part of their treatment regimen, while the comparison group included 113 (49.78%) patients who received standard treatment regimens. Blood levels of VEGF, PDGF-BB, and TGF1β were determined using enzyme-linked immunosorbent assay, and markers of carbohydrate and lipid metabolism were measured using a colorimetric method. The duration of diabetes, the time of ulcer formation and healing rate, and the degree of foot tissue damage according to Wagner were also assessed.</p> <p><bold>Results.</bold><bold> </bold>Healing of diabetic wounds was more active with laser therapy and was associated with increased levels of PDGF-BB (p &lt; 0.001) and TGF1β (p = 0.032), and a decrease in VEGF to control values (p = 0.014). In the comparison group, no relationship was found between TGF1β levels and wound healing (p = 0.252), indicating low fibroblastogenesis activity with traditional diabetic foot treatment. A relationship was found between the decrease in HbA1c in the study group and levels of VEGF (p = 0.001) and PDGF-BB (p &lt; 0.001), but no relationship was found for TGF1β (p = 0.054), which is due to the influence of tissue glycation on the proliferative potential of fibroblasts in diabetic foot disease.</p> <p><bold>Conclusion.</bold><bold> </bold>VEGFА and PDGF-BB growth factors were molecular predictors of the degree of tissue damage in the diabetic foot. Determining the role of growth factors in diabetic wound healing is important for developing a personalized approach to treating diabetic foot syndrome and predicting the risk of complications.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold> – установить взаимосвязи васкулоэндотелиального фактора роста (VEGF), тромбоцитарного фактора роста (PDGF-BB) и трансформирующего фактора роста β1 (TGFβ1) с клинико-диагностическими параметрами у пациентов с синдромом диабетической стопы (СДС) при различных подходах в лечении.</p> <p><bold>Материал и методы.</bold><bold> </bold>В исследовании участвовали 227 пациентов с СДС, которые были разделены на 2 группы. В основную группу включены 114 (50,22%) человек с применением лазеротерапии в комплексе лечения, в группу сравнения – 113 (49,78%) пациентов со стандартными схемами лечения. Содержание в крови факторов роста VEGF, PDGF-ВВ и TGF1β определяли методом иммуноферментного анализа, маркеры углеводного и липидного обмена колориметрическим методом. Учитывались длительность течения СД, время формирования и скорость заживления язвенных дефектов, степень поражения тканей стопы по Вагнеру.</p> <p><bold>Результаты.</bold> Заживление диабетических ран происходило активнее на фоне лечения с лазеротерапией и было связано с увеличением уровня PDGF-ВВ (p &lt; 0,001), TGF1β (p = 0,032), снижением VEGF до контрольных значений (p = 0,014). В группе сравнения между уровнем TGF1β и процессом заживления ран зависимость не установлена (p = 0,252), что свидетельствовало о низкой активности фибробластогенеза при традиционной методике лечения СДС. Определена зависимость снижения HbA1c в основной группе с уровнем VEGF (p = 0,001) и PDGF-ВВ (p &lt; 0,001) и не установлена для TGF1β (p = 0,054), что обусловлено влиянием гликации тканей на пролиферативный потенциал фибробластов при СДС.</p> <p><bold>Заключение.</bold><bold> </bold>Факторы роста VEGFА и PDGF-ВВ являлись молекулярными предикторами степени повреждения тканей диабетической стопы. Определение роли факторов роста в заживлении диабетических ран имеет важное значение для персонифицированного подхода в разработке алгоритма лечения СДС и прогнозирования риска развития осложнений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diabetic foot syndrome</kwd><kwd>growth factors</kwd><kwd>VEGF</kwd><kwd>PDGF-BB</kwd><kwd>TGFβ1</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>синдром диабетической стопы</kwd><kwd>факторы роста</kwd><kwd>VEGF</kwd><kwd>PDGF-BB</kwd><kwd>TGFβ1</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Armstrong D.G., Lavery L.A., Wrobel J.S., Vileikyte L. Quality of life in healing diabetic wounds: does the end justify the means? J. Foot Ankle Surg. 2008; 47: 278–82.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Armstrong D.G., Swerdlow M.A., Armstrong A.A., Conte M.S., Padula W.V., Bus S.A. Five years mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J. Foot Ankle Res. 2020; 13. DOI: 10.1186/s13047-020-00383-2.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Boulton A.J. The Pathway to Foot Ulceration in diabetes. Med. Clin. N. Am. 2013; 97: 775–90.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>International Diabetes Federation. IDF Diabetes Atlas, 9 ed. Brussels, Belgium. 2019; 168.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lavery L.A., Peters E.J., Williams J.R., Murdoch D.P., Hudson A., Lavery D.C. International Working Group on the Diabetic Foot. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care. 2008; 31 (1): 154–6. DOI: 10.2337/dc07-1302</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lazzarini P.A., Pacella R.E., Armstrong D.G., van Netten J.J. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. Diabet Med. 2018; 35 (9): 1297–99.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Blakytny R., Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet. Med. 2006; 23: 594–608.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Nomura S., Shouzu А., Omoto S. Significance of chemokines and activated platelets in patients with diabetes. Clin. Exp. Immunol. 2000; 121: 437–43.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jia G., Aroor A.R., Jia С. Endothelial cell senescence in aging-related vascular dysfunction. Biochim Biophys Acta Mol Basis Dis. 2019; 1865: 1802–9.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Vempati P., Popel A.S., Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine &amp; growth factor reviews. 2014; 25 (1): 1–19. DOI: 10.1016/j.cytogfr.2013.11.002.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Игнатенко Г.А., Бондаренко Н.Н., Дубовая А.В., Игнатенко Т.С., Валигун Я.С., Беляева Е.А., Гавриляк В.Г. Факторы, индуцируемые гипоксией: детали создают «картину». Часть II. HIF-2. Фундаментальная и клиническая медицина. 2023; 8 (4): 85–100. [Ignatenko G.A., Bondarenko N.N., Dubovaya A.V., Ignatenko T.S., Valigun YA.S., Belyaeva E.A., Gavrilyak V.G. Faktory, induciruemye gipoksiej: detali sozdayut «kartinu». CHast’ II. HIF-2. Fundamental’naya i klinicheskaya medicina. 2023; 8 (4): 85–100. doi.org/10.23946/2500-0764-2023-8-4-85-100 (in Russian)].</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Qing C. The molecular biology in wound healing &amp; non-healing wound. Chin. J. Traumatol. 2017; 20 (4): 189–93. doi.org/10.1016/j.cjtee.2017.06.001</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Choi S.H., Ruggiero D., Sorice R., Song C., Nutile T., Vernon Smith A., Concas M.P. et al. Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies. PLoS Genetics. 2016; 12 (2): e1005874. DOI: 10.1371/journal.pgen</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Moustakas A., Heldin P. TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta Gen Subj. 2014; 1840 (8): 2621–34. doi.org/10.1016/j.bbagen.2014.02.004</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Комелягина Е.Ю., Анциферов М.Б. Факторы роста в терапии язвенных дефектов при синдроме диабетической стопы. Сахарный диабет. 2019; 22,4: 377–83. [Komelyagina E.YU, Anciferov M.B. Faktory rosta v terapii yazvennyh defektov pri sindrome diabeticheskoj stopy. Saharnyj diabet. 2019; 22,4: 377–83. DOI: 10.14341/DM10130 (in Russian)].</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Халимов Э.В., Михайлов А.Ю., Иванова Л.М. Тромбоцитарный концентрат в комплексном лечении язвенных дефектов при синдроме диабетической стопы. Труды Ижевской государственной медицинской академии. 2018; 56: 57–8. [Halimov E.V., Mihajlov A.YU., Ivanova L.M. Trombocitarnyj koncentrat v kompleksnom lechenii yazvennyh defektov pri sindrome diabeticheskoj stopy. Trudy Izhevskoj gosudarstvennoj medicinskoj akademii 2018; 56: 57–8 (in Russian)].</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Drela E., Kulwas A., Jundziłł W., Góralczyk B., Boinska J., Drewniak W., Gadomska G., Rość D. VEGF-A and PDGF-BB--angiogenic factors and the stage of diabetic foot syndrome advancement. Endokrynol Pol. 2014; 65 (4): 306–12. DOI: 10.5603/EP.2014.0042</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Теувов А.А., Базиев А.М., Солтанов Э.И. Озон и лазерное излучение в лечении неосложненных форм острых гнойных хирургических заболеваний мягких тканей. Кубанский научный медицинский вестник. 2014; 3,145: 113–5. [Teuvov A.A., Baziev A.M., Soltanov E.I. Ozon i lazernoe izluchenie v lechenii neoslozhnennyh form ostryh gnojnyh hirurgicheskih zabolevanij myagkih tkanej. Kubanskij nauchnyj medicinskij vestnik. 2014; 3,145: 113–5 (in Russian)].</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Koh T., DiPietro L.A. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol. Med. 2011; 13: e23.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Veerman K.J., Venegas-Pino D.E., Shi Y., Khan M.I., Gerstein H.C., Werstuck G.H. Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. Atherosclerosis. 2013; 227 (2): 250–8. DOI: 10.1016/j.atherosclerosis.2013.01.018.</mixed-citation></ref></ref-list></back></article>
